Sibylla Biotech

Sibylla Biotech is an early-stage platform-based drug discovery company,  developing a new generation of small molecule degraders against untreatable diseases.

Sibylla's approach is based on the enabling platform for simulating the folding pathway from the amino acid sequence produced by the cell's ribosomes to the native state. 

This approach allows characterizing previously unexplored and long-lived folding intermediate states with atomic detail. Small molecules binding to pockets in such new therapeutical targets eventually impair the correct folding and lead the protein to degradation. Sibylla's technology is patented as PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting) and enables targeting and degrading proteins that have been considered undruggable so far. 

Sibylla develops a proprietary pipeline of pharmacological programs to license out at the late stages of the drug discovery process, and partners with pharma companies on other programs."